RxNews Recap for Tuesday 12-08-09 Print E-mail
By Mary Davila   
Tuesday, 08 December 2009 21:50
Below is a list of the companies that made news in the healthcare sector on Tuesday, December 08, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Ariba, Inc. (Nasdaq:ARBA), the leading spend management solutions provider, today announced that it has signed a new agreement with CVS Caremark, the largest provider of prescriptions in the nation.

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that David Arkowitz, Executive Vice President, Chief Financial Officer and Chief Business Officer, and Lou Brenner, Senior Vice President, will present an overview of the Company at the Deutsche Bank 2009 Biotech Boston Confab Conference on December 15, 2009 at 12:30 p.m. ET.

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has moved to further enhance its balance sheet via the acquisition of additional equity growth capital from several institutional and private investors.

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

Geron Corporation (Nasdaq:GERN) today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today the successful debut of its new flagship point-of-care (POC) diagnostic reader device, Q-Reader™, at MEDICA 2009 on November 18-21, 2009, in Düsseldorf, Germany.

Medtronic, Inc. (NYSE: MDT), today announced the hire of Prof. Martin Rothman as vice president of medical affairs for the company’s coronary and peripheral vascular business based in Santa Rosa, Calif.

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter